论文部分内容阅读
短期内迅速形成冠心病是心脏移植患者晚期发病及死亡的主要原因。动物实验业已证实钙拮抗剂可抑制实验性动脉粥样硬化的发生,在此研究基础上,作者对接受心脏移植后的患者应用硫氨酮进行前瞻性治疗研究,以评价硫氨酮对心脏移植患者冠心病的预防效果。方法:将符合心脏移植适应症的患者随机分为硫氨酮治疗组(n=52)和非钙抗拮剂治疗组(n=54),两组心脏移植供、受者的年龄、性别、组织相容性抗原(HLA)匹配及移植心脏的缺血发作时间无差别。心脏移植后近期内及以后每年均作冠状动脉造影,测量开始时,第1年及第2年时冠状动脉各分支的平均内径,作为评估冠状动脉病变轻重的指标。结果:接受冠状动脉造影达3次的57例患者
The rapid formation of coronary heart disease in short term is the main cause of late onset and death of heart transplant patients. Animal experiments have confirmed that calcium antagonists can inhibit the development of experimental atherosclerosis. On the basis of this study, the authors prospectively studied the use of lucendronine in patients receiving heart transplantation to evaluate the effects of lucendronate on Prevention of coronary heart disease in heart transplant patients. Methods: Patients eligible for heart transplantation were randomly divided into two groups: treatment group (n = 52) and non-calcium antagonist group (n = 54). The age and sex of the recipients , Histocompatibility antigen (HLA) matching and no difference in ischemic time of transplanted heart. Coronary angiography was performed in the immediate and later years after heart transplantation, and the mean internal diameter of each branch of the coronary arteries at the beginning, the first year and the second year was measured as an index for evaluating the severity of coronary artery lesion. Results: 57 patients undergoing coronary angiography up to 3 times